Quince Therapeutics, Inc. (QNCX)
QNCX moved a median of 0.00% 30 minutes after news, and -0.27% by the close. How QNCX actually reacts to news — the realized, point-in-time move the market made, measured across 222 labeled events over the last three years with zero look-ahead.
QNCX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 34% | 218 |
| 30-min | 0.00% | 48% | 221 |
| 60-min | -0.07% | 42% | 221 |
| to close | -0.27% | 44% | 216 |
| Middle 50% of QNCX reactions | -1.57% to +1.94% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 222 |
Half of all Quince Therapeutics, Inc. news events land between -1.57% and +1.94% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How QNCX reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst downgrades | 13 | -10.60% | 31% | -20.55% |
| Coverage initiations | 32 | +0.62% | 56% | -0.42% |
| Rating reiterations | 28 | +0.08% | 50% | +0.30% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how QNCX ranks against every other measured name →
That’s how QNCX usually reacts — get an email when it moves on news →Email me when QNCX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to QNCX's baseline. Nothing else.
Recent QNCX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K Quince Therapeutics, For: Oct 07 | SEC filing · Form 8-K | SEC EDGAR | +1.31% | +4.03% | |
| Quince Therapeutics Relaunches as IRulya Therapeutics with a Focus on the Clinical Development of LAM-001, Targeting a Key Pathway in Pulmonary Disease | Press release | GlobeNewswire | +1.31% | +4.03% | |
| Form S-8 Quince Therapeutics, | SEC filing · Form S-8 | SEC EDGAR | +1.31% | +4.03% | |
| Form 8-K Quince Therapeutics, For: Oct 06 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -0.07% | |
| Form 8-K Quince Therapeutics, For: Sep 30 | SEC filing · Form 8-K | SEC EDGAR | +0.37% | -2.96% | |
| Form DEFA14A Quince Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | +0.37% | -2.96% | |
| Quince Therapeutics to Host Virtual KOL Event to Discuss the Current Treatment Landscape for PH-ILD and BOS and the Role for LAM-001 as a Potential Therapeutic Option on September 28, 2026 | Press release | GlobeNewswire | +0.00% | -0.59% | |
| Form 8-K Quince Therapeutics, For: Sep 08 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.96% | |
| Form 8-K Quince Therapeutics, For: Aug 31 | SEC filing · Form 8-K | SEC EDGAR | +0.03% | +2.59% | |
| Quince Therapeutics to Participate in September 2026 Investor Conferences | Press release | GlobeNewswire | +0.00% | -7.31% | |
| Form 8-K Quince Therapeutics, For: Aug 23 | SEC filing · Form 8-K | SEC EDGAR | -0.33% | +2.55% | |
| Form DEF 14A Quince Therapeutics, For: Oct 06 | SEC filing · Form DEF | SEC EDGAR | +0.00% | -4.54% | |
| Form EFFECT Quince Therapeutics, | SEC filing · Form EFFECT | SEC EDGAR | +0.00% | -4.54% | |
| Form 8-K Quince Therapeutics, For: Aug 17 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -2.38% | |
| Form 10-Q Quince Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | -2.38% | |
| Form 8-K Quince Therapeutics, For: Aug 14 | SEC filing · Form 8-K | SEC EDGAR | +5.32% | +7.11% | |
| Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update | Press release | GlobeNewswire | +5.32% | +7.11% | |
| Form S-3/A Quince Therapeutics, | SEC filing · Form S-3 | SEC EDGAR | +0.00% | +6.33% | |
| Form 8-K Quince Therapeutics, For: Jul 29 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +4.81% | |
| Form PRE 14A Quince Therapeutics, For: Jul 31 | SEC filing · Form PRE | SEC EDGAR | +0.00% | +4.81% | |
| Form S-3 Quince Therapeutics, | SEC filing · Form S-3 | SEC EDGAR | +0.00% | +4.81% | |
| Form 8-K/A Quince Therapeutics, For: May 17 | SEC filing · Form 8-K | SEC EDGAR | +0.87% | +5.59% | |
| Quince Therapeutics Appoints Recognized Leaders in Pulmonary Medicine to Scientific Advisory Board | Press release | GlobeNewswire | -2.16% | -1.78% | |
| Form 8-K Quince Therapeutics, For: Jun 26 | SEC filing · Form 8-K | SEC EDGAR | -0.03% | -0.35% | |
| Form 8-K/A Quince Therapeutics, For: Jun 26 | SEC filing · Form 8-K | SEC EDGAR | -1.05% | -1.01% | |
| Form 8-K Quince Therapeutics, For: Jun 11 | SEC filing · Form 8-K | SEC EDGAR | +3.74% | -0.65% | |
| Form D Quince Therapeutics, | SEC filing · Form D | SEC EDGAR | +0.12% | +5.15% | |
| Form 8-K Quince Therapeutics, For: May 20 | SEC filing · Form 8-K | SEC EDGAR | +3.08% | +5.77% | |
| Form 8-K Quince Therapeutics, For: May 17 | SEC filing · Form 8-K | SEC EDGAR | +5.26% | +4.72% | |
| Form 8-K/A Quince Therapeutics, For: May 17 | SEC filing · Form 8-K | SEC EDGAR | -3.75% | +2.88% | |
| Quince Announces Acquisition of Orphai and up to $187 Million Private Placement to Advance Pulmonary Pipeline | Press release | GlobeNewswire | -29.63% | -26.31% | |
| Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD | Press release | GlobeNewswire | -29.63% | -26.31% | |
| UPDATE - Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD | Press release | GlobeNewswire | +3.52% | -12.35% | |
| Form 10-Q Quince Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.41% | +3.28% | |
| Form 8-K Quince Therapeutics, For: Apr 27 | SEC filing · Form 8-K | SEC EDGAR | +0.81% | -0.81% | |
| Form ARS Quince Therapeutics, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -1.26% | -1.60% | |
| Form DEF 14A Quince Therapeutics, For: Jun 11 | SEC filing · Form DEF | SEC EDGAR | -1.26% | -1.60% | |
| Form DEFA14A Quince Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | -1.26% | -1.60% | |
| Form 8-K Quince Therapeutics, For: Apr 22 | SEC filing · Form 8-K | SEC EDGAR | +4.75% | -0.73% | |
| Form PRE 14A Quince Therapeutics, For: Jun 11 | SEC filing · Form PRE | SEC EDGAR | +2.80% | +1.60% | |
| Form S-8 Quince Therapeutics, | SEC filing · Form S-8 | SEC EDGAR | +2.80% | +1.60% | |
| Form 10-K Quince Therapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -3.88% | +9.30% | |
| Form 8-K Quince Therapeutics, For: Apr 09 | SEC filing · Form 8-K | SEC EDGAR | +3.26% | -1.67% | |
| Form NT 10-K Quince Therapeutics, For: Dec 31 | SEC filing · Form NT | SEC EDGAR | -5.40% | -1.00% | |
| Form 8-K Quince Therapeutics, For: Mar 27 | SEC filing · Form 8-K | SEC EDGAR | -7.94% | -9.63% | |
| Quince Therapeutics Settles Approximately $16.4 Million of Debt | Press release | Business Wire | -7.94% | -9.63% | |
| Form 8-K Quince Therapeutics, For: Mar 16 | SEC filing · Form 8-K | SEC EDGAR | -1.52% | +18.83% | |
| Form 8-K Quince Therapeutics, For: Feb 12 | SEC filing · Form 8-K | SEC EDGAR | -1.78% | -42.18% | |
| Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives | Press release | Business Wire | +14.57% | +88.46% | |
| Form 8-K Quince Therapeutics, For: Jan 30 | SEC filing · Form 8-K | SEC EDGAR | -5.85% | -20.55% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the QNCX section they belong to.
Where else QNCX is measured.
QNCX earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Quince Therapeutics, Inc.'s median reaction calculated?
Every labeled QNCX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 222 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 48% of QNCX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does QNCX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.